Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
In a groundbreaking study published in the June 2026 issue of Oncotarget, researchers from the Dana-Farber Cancer Institute have unveiled ...
A newly published study from Karolinska Institutet has illuminated a critical factor that may undermine the effectiveness of cancer immunotherapy—neutrophils, ...
For decades, the phenomenon of T cell exhaustion in tumors has puzzled immunologists and oncologists alike. Mitochondrial dysfunction has long ...
In a groundbreaking development that challenges prevailing paradigms of cancer immunotherapy resistance, researchers have unveiled a novel intrinsic mechanism by ...
In a groundbreaking international collaboration, researchers from Moffitt Cancer Center, the Karolinska Institutet, and the University of Texas MD Anderson ...
In a dramatic revelation that challenges conventional thinking about cell biology, scientists report that cancer cells can effectively “poison” the ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine